RESUMO
Zinc oxide nanoparticles (ZnO-NPs) are increasingly used in sunscreens, food additives, pigments, rubber manufacture, and electronic materials. Several studies have shown that ZnO-NPs inhibit cell growth and induce apoptosis by the production of oxidative stress in a variety of human cancer cells. However, the anti-cancer property and molecular mechanism of ZnO-NPs in human gingival squamous cell carcinoma (GSCC) are not fully understood. In this study, we found that ZnO-NPs induced growth inhibition of GSCC (Ca9-22 and OECM-1 cells), but no damage in human normal keratinocytes (HaCaT cells) and gingival fibroblasts (HGF-1 cells). ZnO-NPs caused apoptotic cell death of GSCC in a concentration-dependent manner by the quantitative assessment of oligonucleosomal DNA fragmentation. Flow cytometric analysis of cell cycle progression revealed that sub-G1 phase accumulation was dramatically induced by ZnO-NPs. In addition, ZnO-NPs increased the intracellular reactive oxygen species and specifically superoxide levels, and also decreased the mitochondrial membrane potential. ZnO-NPs further activated apoptotic cell death via the caspase cascades. Importantly, anti-oxidant and caspase inhibitor clearly prevented ZnO-NP-induced cell death, indicating the fact that superoxide-induced mitochondrial dysfunction is associated with the ZnO-NP-mediated caspase-dependent apoptosis in human GSCC. Moreover, ZnO-NPs significantly inhibited the phosphorylation of ribosomal protein S6 kinase (p70S6K kinase). In a corollary in vivo study, our results demonstrated that ZnO-NPs possessed an anti-cancer effect in a zebrafish xenograft model. Collectively, these results suggest that ZnO-NPs induce apoptosis through the mitochondrial oxidative damage and p70S6K signaling pathway in human GSCC. The present study may provide an experimental basis for ZnO-NPs to be considered as a promising novel antitumor agent for the treatment of gingival cancer.
Assuntos
Apoptose/efeitos dos fármacos , Carcinoma de Células Escamosas/metabolismo , Neoplasias Gengivais/metabolismo , Mitocôndrias/metabolismo , Nanopartículas/química , Proteínas Quinases S6 Ribossômicas 70-kDa/metabolismo , Transdução de Sinais/efeitos dos fármacos , Óxido de Zinco/farmacologia , Caspases/metabolismo , Morte Celular/efeitos dos fármacos , Gengiva , Humanos , Queratinócitos/metabolismo , Potencial da Membrana Mitocondrial/efeitos dos fármacos , Estresse Oxidativo/efeitos dos fármacos , Fosforilação , Espécies Reativas de Oxigênio/metabolismoRESUMO
AIMS/INTRODUCTION: Studies suggest that salivary proteins can be used as potential non-invasive markers for clinical diagnosis and screening for diabetes. Previous reports showed that plasma alpha 2-macroglobulin (A2MG) levels were higher in diabetic patients, especially with diabetic complications. We investigated the relationship between salivary A2MG values and clinical characteristics in patients with type 2 diabetes. MATERIALS AND METHODS: A total of 91 adults were recruited from our outpatient clinics. The study the patients' collected general and biochemical data, and blood glucose (fasting glucose, glycated hemoglobin [HbA1c]) data. Plasma and salivary A2MG levels were examined by enzyme-linked immunosorbent assay. RESULTS: The salivary A2MG levels were significantly positively correlated with plasma A2MG levels, fasting glucose HbA1c and periodontitis status. After 3 months of follow up, the net change of salivary A2MG values positively correlated with the net change of fasting glucose, HbA1c and triglyceride levels, but negatively correlated with high-density lipoprotein cholesterol changes. Furthermore, the correlations between salivary A2MG and fasting glucose HbA1c were better than plasma A2MG, respectively. CONCLUSIONS: Our data show that salivary A2MG levels have better correlation with fasting glucose HbA1c and periodontitis status than plasma A2MG in diabetic patients. Salivary A2MG concentration might serve as a non-invasive marker for clinical diabetic control.
Assuntos
Diabetes Mellitus Tipo 2/metabolismo , Saliva/metabolismo , alfa-Macroglobulinas/metabolismo , Biomarcadores/sangue , Biomarcadores/metabolismo , Glicemia , Diabetes Mellitus Tipo 2/diagnóstico , Hemoglobinas Glicadas/metabolismo , HumanosRESUMO
OBJECTIVE: The study aims to evaluate the efficacy of combination therapy with propylthiouracil (PTU) and cholestyramine in the treatment of Graves' hyperthyroidism. BACKGROUND: Thyroxine (T4) is metabolized mainly in the liver by conjugation to glucuronides and sulphates that enter the enterohepatic circulation. Thyrotoxic patients have an abnormal increase in thyroid hormone in their enterohepatic circulation. Previous studies on combination therapy with methimazole and cholestyramine for Graves' hyperthyroidism have shown it to be an effective adjunctive treatment. In this study, we examined the efficacy of combination therapy with PTU and cholestyramine in the treatment of Graves' hyperthyroidism. METHODS: Thirty patients with newly diagnosed Graves' hyperthyroidism were randomly divided into two groups: group I (n = 15) received PTU 100 mg twice a day, propranolol 40 mg twice a day and cholestyramine 4 g twice a day for 4 weeks; group II (n = 15) received PTU 100 mg twice a day and propranolol 40 mg twice a day for 4 weeks. The therapeutic efficacy was determined by serum total triiodothyronine (TT3), free thyroxine (FT4) and TRAb levels at baseline, and at the end of 2 and 4 weeks during the study period. RESULTS: There was no significant difference in baseline thyroid function parameters. At the end of 2 and 4 weeks of the study period, serum TT3 and FT4 levels of group I were significantly lower than those of group II. No significant differences in the TRAb level were found between the two groups. CONCLUSION: Cholestyramine contributed to a more rapid and complete decline in thyroid hormone levels in patients with Graves' hyperthyroidism. It was thus proved to be an effective and well-tolerated adjunctive therapy.